Showing 4081-4090 of 10823 results for "".
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual prop
- Hoth Therapeutics, Inc.’s BioLexa in AD: So Far, So Safehttps://practicaldermatology.com/news/hoth-therapeutics-incs-biolexa-in-ad-so-far-so-safe/2460853/Hoth Therapeutics, Inc.’s BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed, according to the safety results in Cohort 1 of its first in human clinical trial of the BioLexa platform to treat atopic dermatitis.
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operati
- Thumbs Down for Neothetics, Inc.'s LIPO-202; Stock Plummetshttps://practicaldermatology.com/news/thumbs-down-for-neothetics-incs-lipo-202/2458145/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares droppe
- Consensus Paper Addresses S. aureus Exacerbated ADhttps://practicaldermatology.com/news/consensus-paper-addresses-s-aureus-exacerbated-ad/2468445/A significant unmet need exists for a single topical atopic dermatitis (AD) therapy effective against all symptoms—including pruritis, S. aureus-driven AD exacerbation, infection, and inflammation—across AD severity levels, according to a panel of six pediatric dermatologists who participated in
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but
- Robert T. Kelley of Caliber Imaging & Diagnostics Named Vice President of US Saleshttps://practicaldermatology.com/news/20140305-robert_t_kelley_of_caliber_imaging__diagnostics_named_vice_president_of_us_sales/2459325/Caliber Imaging and Diagnostics has declared Robert T. Kelley vice president of US sales. Kelley, originally director of clinical sales since 2011, was due for a promotion. "We are delighted to promote Bob to Vice President of Sales, just as we were truly fortunate when he agreed to join
- Allergan Vet Julian S. Gangolli Joins Revance's Board of Directorshttps://practicaldermatology.com/news/allergan-vet-julian-s-gangolli-joins-revances-board-of-directors/2458508/Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, is now on Revance's Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016. He will help Revance progress toward regulatory approv
- Eczema Breakthrough: S. aureus Evolve to a Variant with a Mutation in a Specific Gene to Grow Fasterhttps://practicaldermatology.com/news/eczema-breakthrough-s-aureus-evolve-to-a-variant-with-a-mutation-in-a-specific-gene-to-grow-faster/2461659/New research shows how Staphylococcus aureus gains mutations that allow it to colonize eczema patches. In people with eczema, S. aureus tends to evolve to a variant with a mutation in a specific gene that helps it grow faster on the skin. This study marks the first t
- Allergan Appoints Douglas S. Ingram as Presidenthttps://practicaldermatology.com/news/20130702-allergan_appoints_douglas_s_ingram_as_president/2459504/Douglas S. Ingram was appointed as President of Allergan. In this role, Mr. Ingram will lead the company's global commercial operations, with responsibility for the company's broad portfolio of pharmaceutical, consumer, and medical device product